<DOC>
	<DOCNO>NCT01822184</DOCNO>
	<brief_summary>Hunter syndrome ( Mucopolysaccharidosis II , [ MPS II ] ) rare , genetically link lysosomal storage disease ( LSD ) cause deficiency enzyme , iduronate-2-sulfatase ( I2S ) . Most MPS II patient present degree neurodevelopmental involvement , range severe cognitive impairment behavioral problem mildly impaired cognition . This observational study ; investigational treatment administer . The primary objective study evaluate neurodevelopmental status pediatric patient MPS II time gain information guide future treatment study patient population .</brief_summary>
	<brief_title>Observational Study Evaluate Neurodevelopmental Status Pediatric Patients With Hunter Syndrome ( MPS II )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis II</mesh_term>
	<criteria>Patients must meet follow criterion consider eligible enrollment : 1. . The patient deficiency iduronate2sulfatase enzyme activity AND b . The patient document mutation iduronate2sulfatase gene . OR c. The patient normal enzyme activity level one sulfatase 2 . The patient male , least 2 year age less 18 year age time informed consent . 3 . The patient must sufficient auditory capacity enrollment , without hear aid , Investigator 's judgment complete require protocol testing , compliant wear aid schedule study visit . 4 . The patient , patient 's parent ( ) , legally authorize guardian ( ) voluntarily sign Institutional Review Board / Independent Ethics Committeeapproved inform consent and/or assent form ( ) , applicable . Patients meet follow criterion exclude study . 1 . The patient clinically significant nonHunter syndromerelated CNS involvement medical psychiatric comorbidity ( y ) , investigator 's judgment , may interfere accurate administration interpretation protocol assessment , affect study data , confound integrity study result . 2 . The patient general conceptual ability score ( GCA ) developmental quotient cognitive scale 55 Screening . 3 . The patient participate interventional clinical trial participate interventional clinical trial within 30 day prior enrollment ; participation non interventional observational study permit .</criteria>
	<gender>Male</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Neurodevelopmental Status</keyword>
	<keyword>Pediatric Hunter syndrome patient</keyword>
	<keyword>Central Nervous System ( CNS ) involvement</keyword>
	<keyword>Observational study</keyword>
	<keyword>Cognitive impairment</keyword>
</DOC>